300 related articles for article (PubMed ID: 31216825)
1. [Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors].
Huang HF; Zhu H; Yang XT; Guo XY; Li SS; Xie Q; Tian XB; Yang Z
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):410-414. PubMed ID: 31216825
[TBL] [Abstract][Full Text] [Related]
2. [Role of PD-1/PD-L1 in microenvironment of breast cancer].
Ji P; Gong Y; Hu X
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):401-405. PubMed ID: 31216823
[TBL] [Abstract][Full Text] [Related]
3. PD-1 /PD-L1 checkpoint in hematological malignancies.
Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
[TBL] [Abstract][Full Text] [Related]
4. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
8. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
Qin W; Hu L; Zhang X; Jiang S; Li J; Zhang Z; Wang X
Front Immunol; 2019; 10():2298. PubMed ID: 31636634
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.
Pawłowska A; Suszczyk D; Okła K; Barczyński B; Kotarski J; Wertel I
Clin Exp Immunol; 2019 Mar; 195(3):334-344. PubMed ID: 30582756
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
13. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of response to PD-1/PD-L1 inhibition.
Maleki Vareki S; Garrigós C; Duran I
Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
[TBL] [Abstract][Full Text] [Related]
15. PD-1 and its ligands are important immune checkpoints in cancer.
Dong Y; Sun Q; Zhang X
Oncotarget; 2017 Jan; 8(2):2171-2186. PubMed ID: 27974689
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
18. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]